Patents by Inventor Trixi Brandl

Trixi Brandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200330435
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Publication number: 20190038600
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 7, 2019
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Patent number: 10154990
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Publication number: 20160136133
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 29, 2015
    Publication date: May 19, 2016
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Patent number: 9290485
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 22, 2016
    Assignee: NOVARTIS AG
    Inventors: Trixi Brandl, Stefanie Flohr, Sebastian Kopec, Julie Lachal, Christian Markert, Kenji Namoto, Perle Nganga, Bernard Pirard, Martin Renatus, Richard Sedrani, Thomas Zoller
  • Patent number: 9206232
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 8, 2015
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Publication number: 20140357551
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Publication number: 20140350034
    Abstract: The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: January 25, 2013
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Trixi Brandl, Stefanie Flohr, Christian Markert, Kenji Namoto, Bernard Pirard, Martin Renatus
  • Publication number: 20140296217
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 2, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Edward PARK, Gerald Juergen ROTH, Armin HECKEL, Nveed CHAUDHARY, Trixi BRANDL, Georg DAHMANN, Matthias GRAUERT
  • Patent number: 8840878
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8613914
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8512690
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8445527
    Abstract: The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Patent number: 8410100
    Abstract: New compounds of Formula (1) are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: April 2, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Sara Frattini, Trixi Brandl, Steffen Breitfelder, Enzo Cereda, Matthias Grauert, Matthias Hoffman, Anne T. Joergensen, Udo Maier, Alexander Pautsch, Monica Quai, Stefan Scheuerer
  • Publication number: 20130034519
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • Publication number: 20130022572
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 24, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • Patent number: 8354418
    Abstract: The present invention relates to compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: January 15, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Trixi Brandl, Udo Maier, Christoph Hoenke, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Matthias Hoffmann, Stefan Scheuerer, Klaus Erb, Michael Pieper, Ingo Pragst
  • Patent number: 8334378
    Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: December 18, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Trixi Brandl, Udo Maier, Matthias Hoffmann, Stefan Scheuerer, Anne T. Joergensen, Alexander Pautsch, Steffen Breitfelder, Matthias Grauert, Christoph Hoenke, Klaus Erb, Michael Pieper, Ingo Pragst
  • Publication number: 20120231998
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Patent number: 8232286
    Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Breitfelder, Udo Maier, Trixi Brandl, Christoph Hoenke, Matthias Grauert, Alexander Pautsch, Matthias Hoffmann, Frank Kalkbrenner, Anne T. Joergensen, Gerhard Schaenze, Stefan Peters, Frank Buettner, Eckhart Bauer